Loading
Contineum Therapeutics, Inc. Stock: price and insider trades · United States
Contineum Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Contineum Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. From 22 October 2025 to 22 October 2026, the disclosure feed for Contineum Therapeutics, Inc. logged 54 filings by 6 insiders.
All open-market trades in the period are sales: 27 sales worth €1.1M, by 3 insiders, with no purchase on record. Watkins Tim filed the largest sale, €152k, on 1 July 2026.
For context, the typical company on the same exchange (median of 5,461 companies) published 27 filings over the same period, against 54 filings here. Our records for Contineum Therapeutics, Inc. go back to 2024, with no purchases and 30 sales on the open market in total.
The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
61
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€1M
30 ops. · all time
Who traded when
BuySaleDaniel S. Lorrain18 sales
Carmine N. Stengone7 sales
Tim Watkins5 sales
Analyst consensus: bullish or bearish?
Analysts rate Contineum Therapeutics, Inc. Buy (bullish), based on 7 analysts. Average price target: US$22.14.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.13
Analyst consensus
7 analystsBuy
US$14.00Target US$22.14(+211%)US$30.00
Income statement
EBITDA-US$67.7M
Net income-US$60M0.0% margin
Valuation
PER (forward)-3.7x
P/Book1.1x
Beta0.86
Balance sheet & cash
Market capUS$268.2M
Total debtUS$8.3M
Free Cash Flow-US$55.5M
Debt / Equity3%
Profitability & ownership
ROE-28.0%
ROA-19.2%
% insiders0.1%
% institutions93.5%
Last declaration on 1 October 2026
Declarations61 total
4,170 shares@ US$13.420.012% mcap8.7% of flowCommonSEC144:0001950047-26-009932
2,500 shares@ US$16.700.0086% mcap15.4% of flowCommonSEC144:0001950047-26-009206
2,500 shares@ US$1.010.0005% mcap1.9% of flowClass A Common StockSEC:0001628280-26-060962:0
2,500 shares@ US$16.45660.0085% mcap30.3% of flowClass A Common StockSEC:0001628280-26-060962:1
9,520 shares@ US$15.490.031% mcap100.0% of flowCommonSEC144:0001950047-26-007509
2,500 shares@ US$15.490.0081% mcap14.4% of flowCommonSEC144:0001950047-26-007517
2,500 shares@ US$1.010.0005% mcap1.9% of flowClass A Common StockSEC:0001628280-26-052031:0
2,500 shares@ US$16.01160.0084% mcap29.7% of flowClass A Common StockSEC:0001628280-26-052031:1
1,015 shares@ US$1.010.0002% mcap0.2% of flowClass A Common StockSEC:0001628280-26-047909:0
1,015 shares@ US$16.000.0034% mcap3.3% of flowClass A Common StockSEC:0001628280-26-047909:1
25 shares@ US$1.010.0000% mcap0.0% of flowClass A Common StockSEC:0001628280-26-047909:2
25 shares@ US$16.000.0001% mcap0.1% of flowClass A Common StockSEC:0001628280-26-047909:3
2,500 shares@ US$14.560.0077% mcap13.7% of flowCommonSEC144:0001950047-26-006968
2,500 shares@ US$1.010.0005% mcap1.9% of flowClass A Common StockSEC:0001628280-26-047710:0
2,500 shares@ US$16.000.0084% mcap30.0% of flowClass A Common StockSEC:0001628280-26-047710:1
9,520 shares@ US$16.390.033% mcap26.6% of flowCommonSEC144:0001950047-26-006723
10,833 shares@ US$16.024278.7% of flowClass A Common StockSEC:0001628280-26-046654:1
7,500 sharesClass A Common StockSEC:0001628280-26-046653:0
10,000 shares@ US$16.00854.6% of flowClass A Common StockSEC:0001628280-26-046653:2
2,500 sharesClass A Common StockSEC:0001628280-26-046653:1
10,833 sharesClass A Common StockSEC:0001628280-26-046654:0
10,833 shares@ US$15.000.034% mcap100.0% of flowCommonSEC144:0001950047-26-006664
10,000 shares@ US$15.000.032% mcap56.5% of flowCommonSEC144:0001950047-26-006666
28,826 shares@ US$15.000.091% mcap73.4% of flowCommonSEC144:0001950047-26-006667
4,170 shares@ US$13.15640.011% mcap10.9% of flowClass A Common StockSEC:0001628280-26-039641:0
25 of 61 declarations
About Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc. (ticker: CTNM) is a U.S.-listed biopharmaceutical company traded on NASDAQ in the United States, and it is best viewed as a clinical-stage biotech rather than a commercial-stage drug maker. The company is headquartered in San Diego, California, and was incorporated in Delaware in 2009. In November 2023, it changed its name from Pipeline Therapeutics, Inc. to Contineum Therapeutics, Inc. to reflect a broader focus on neuroscience, inflammation, and immunology, or NI&I. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1855175/000162828026030614/ctnm-20260331.htm?utm_source=openai))
Contineum’s core business is the discovery and development of novel oral small-molecule therapeutics aimed at diseases with significant unmet medical need. The company’s model is centered on internal R&D and clinical advancement, not on generating revenue from marketed products. Its lead asset is PIPE-791, a brain-penetrant LPA1 receptor antagonist being developed for idiopathic pulmonary fibrosis (IPF). Another key program is PIPE-307, a selective muscarinic M1 receptor antagonist being advanced in neurological indications. Contineum has also nominated CTX-343, a peripherally restricted LPA1R antagonist, underscoring that the company is building a multi-asset discovery platform around related biology. ([contineum-tx.com](https://contineum-tx.com/pipeline/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Contineum occupies a specialized niche within the biotech universe. Its investment case is built on scientific differentiation, target validation, and the ability to move programs through the clinic with convincing safety and efficacy data. The portfolio spans two attractive therapeutic themes: fibrosis/respiratory disease through PIPE-791 and central nervous system disease through PIPE-307. A notable strategic feature is the global license and development agreement with Janssen for PIPE-307, which provides external validation and potentially broadens the path to development and future value creation. ([ir.contineum-tx.com](https://ir.contineum-tx.com/news-releases/news-release-details/pipeline-therapeutics-announces-global-license-and-development/?utm_source=openai))
Recent company highlights have centered on clinical execution and milestone delivery. Throughout 2025, Contineum reported financial and operational updates showing higher R&D spending, largely driven by advancement of PIPE-791 and PIPE-307, while also pointing to upcoming topline clinical readouts. For equity investors, CTNM should therefore be seen as a high-risk, high-upside clinical biotech with a clearly defined pipeline, meaningful scientific ambition, and significant dependence on trial outcomes and partnership execution. ([ir.contineum-tx.com](https://ir.contineum-tx.com/news-releases/news-release-details/contineum-therapeutics-reports-second-quarter-2025-financial/?utm_source=openai))
